2seventy bio, Inc. (TSVT)
NASDAQ: TSVT · Real-Time Price · USD
2.610
-0.070 (-2.61%)
Feb 21, 2025, 4:00 PM EST - Market closed
2seventy bio Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for 2seventy bio stock have an average target of 8.50, with a low estimate of 5.00 and a high estimate of 12. The average target predicts an increase of 225.67% from the current stock price of 2.61.
Analyst Consensus: Buy
* Price targets were last updated on Jul 29, 2024.
Analyst Ratings
The average analyst rating for 2seventy bio stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 5 | 5 | 5 | 5 | 5 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $7 → $6 | Hold | Maintains | $7 → $6 | +129.89% | Jul 29, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +91.57% | Jun 27, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $12 → $11 | Strong Buy | Maintains | $12 → $11 | +321.46% | May 9, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $9 → $12 | Strong Buy | Maintains | $9 → $12 | +359.77% | Apr 8, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | +91.57% | Mar 18, 2024 |
Financial Forecast
Revenue This Year
48.67M
from 100.39M
Decreased by -51.52%
Revenue Next Year
67.01M
from 48.67M
Increased by 37.70%
EPS This Year
-1.02
from -4.42
EPS Next Year
-0.41
from -1.02
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 58.5M | 94.4M | 109.3M | |||
| Avg | 48.7M | 67.0M | 86.6M | |||
| Low | 40.2M | 46.8M | 59.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -41.7% | 94.0% | 63.1% | |||
| Avg | -51.5% | 37.7% | 29.2% | |||
| Low | -60.0% | -3.8% | -11.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.94 | -0.09 | 0.30 |
| Avg | -1.02 | -0.41 | -0.13 |
| Low | -1.20 | -0.86 | -0.76 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.